Citation From: ORTHOKNOW® - September 2014
The fracture repair market stands to remain one of the stronger orthopaedic segments over the next five years based upon its reach across all demographics. A closer look at notable technologies recently launched or still in development, though, indicates a focus on compromised or low-quality bone, mainly found in the older population.
Nearly nine million osteoporosis-related fractures—one every three seconds—occur worldwide annually, according to the International Osteoporosis Foundation (IOF). Of these fractures, 1.7 million occurred at the forearm, 1.6 million at the hip and 1.4 million were clinical vertebral fractures in 2000, the latest data available from IOF.
To be successful, innovative products must meet the needs of the aging population and recognize industry’s clinical and economic pressures, such as the demand for less invasive procedures, quicker recovery time and fewer complications. Here are a few emerging companies—and their technologies—seeking to realize that definition of success.
Arxis is a biomaterial under development for use in multiple applications for the regeneration of diseased bone, cartilage and other soft tissues.
- May be employed as a minimally invasive injectable therapy or as a preformed implant
- Provides mechanical support to an injury site while stimulating tissue regeneration
- “Twin-base linker” molecules, made of carbon, nitrogen and oxygen and packed with antibiotics and bone growth factors, aggregate as a liquid at room temperature and solidify at body temperature, easily integrating with bone.
The Serpentine Composite Grafting System may be used to treat vertebral body compression fractures and subchondral bone insufficiency. Element Orthopedics expects to pursue U.S. clearance and CE Mark approval for the technology.
- Physicians concurrently inject bead-chain solids and a fluent settable material into bone, controlling the deposition of fill material, including location, direction, quantity of fill material and flow
- Beads and fluent materials are injected without using pressure through a gun that has three modes – forward, reverse and cut
The early-stage device company developed OptOssol Hand Compression Screws and Rods. “Optimized Osteogenesis Solutions” (OptOssol) includes a scalable portfolio for the hand, wrist, humerus and other applications.
- Designed to enable higher compression of small fragments to support better bone healing
- Used to treat scaphoid bone, which is prone to nonunions
The Photodynamic Bone Stabilization System is CE Mark approved for fracture alignment reduction in light- to low-load-bearing bones.
- Utilizes a light-curable polymer contained within an expandable PET balloon catheter to achieve stabilization
- Procedure performed through small percutaneous surgical approach • Cured implant conforms to the geometry of a patient’s intramedullary canal
Woven Orthopedic Technologies
The biotextile startup intends to seek U.S. and Europe regulatory approval in 2015 for its system that addresses screw failure by increasing screw and bone fixation.
- Implant is placed into bone prior to screw insertion
- Manufactured to work in conjunction with all screw types
- Uses materials found in other popular implants
These and 11 other entities were selected as emerging companies that may not be on your radar for the latest ORTHOWORLD® report, NOTABLE U.S. COMPANIES IN FRACTURE REPAIR. Some are differentiated based upon innovation in product design, others by manufacturing and delivery. The profiles provide company and product descriptions, regulatory status, value proposition and insight as to whether companies seek to become long-term players in the market or acquisition targets.
Big Numbers and Players in the Fracture Repair Market
Fracture repair is expected to remain a strong growth segment, along with extremities and arthroscopy/soft tissue. Here’s an overview of the market as cited from THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®. Remember, the report is a Member benefit. Download it here.
Worldwide fracture repair product sales reached an estimated $6.5 billion in 2013, an increase of 6.6 percent over 2012.
The segment is projected to experience mid-single-digit growth for each of the next five years and reach $8.35 billion in 2018.
DePuy Synthes dominates the fixation segment, holding an estimated 47 percent of the market share globally in 2013. Stryker, Smith & Nephew, Zimmer, Biomet, Acumed and Orthofix also hold a significant presence, combining to make up 38 percent of the market share.
Published at Orthoworld